Kansas is currently home to 950 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Wichita, Kansas City, Overland Park and Topeka. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Blue Light Cystoscopy With Cysview® Registry
NCT02660645
Recruiting
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Bladder Cancer
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Children's Mercy Hospitals, Kansas City, Kansas
Conditions: Langerhans Cell Histiocytosis
Register for Updates
Changing Talk Online Training (CHATO) National Trial
NCT04610944
Recruiting
The National Plan to Address Alzheimer's disease has identified education of dementia care providers as a top priority to address the need for quality care for the population of persons with dementia that will triple in the next 30 years. This study will test new online interactive training for nursing home staff that improves staff communication and also reduces behavioral symptoms of persons with dementia that they care for. Innovative approaches to reach care providers are essential to achiev... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2023
Locations: University of Kansas School of Nursing, Kansas City, Kansas
Conditions: Dementia, Alzheimer Disease, Communication
Register for Updates
Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites
NCT04288921
Recruiting
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx Influenza A/B + RSV Test at Point of Care Testing Sites
Gender:
All
Ages:
All
Trial Updated:
03/10/2023
Locations: New Medical, Wichita, Kansas
Conditions: Influenza, Human, Respiratory Syncytial Virus Infections
Register for Updates
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Overland Park, Kansas
Conditions: Cystic Fibrosis
Register for Updates
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
NCT05364645
Recruiting
This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small cell lung cancer that is stage IV or has not responded to previous RET directed therapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selpercatinib may st... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: HaysMed University of Kansas Health System, Hays, Kansas
Conditions: Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
NCT04768868
Recruiting
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2023
Locations: University of Kansas Clinical Research Center, Fairway, Kansas
Conditions: Advanced Solid Tumors
Register for Updates
The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation
NCT05012605
Recruiting
Sleep is critical for health and quality of life; however, little is known about the prevalence or impact of non obstructive sleep apnea (non-OSA) sleep disorders in people with stroke. The proposed study aims to characterize the proportion of people with stroke that have non-OSA sleep disorders and their impact on recovery of activities of daily living, functional mobility, and participation along the continuum of recovery in people with stroke.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2023
Locations: KU Medical Center, The University of Kansas, Kansas City, Kansas
Conditions: Stroke, Sleep Wake Disorders, Rehabilitation, Recovery of Function
Register for Updates
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
NCT04266197
Recruiting
The objectives of this study are to evaluate the effects of RT234 on exercise parameters assessed by a specialized exercise test (Cardiopulmonary Exercise Test or CPET) in patients with pulmonary arterial hypertension (PAH).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/09/2023
Locations: The University of Kansas Medical Center, Kansas City, Kansas
Conditions: Pulmonary Arterial Hypertension
Register for Updates
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
NCT03533816
Recruiting
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/07/2023
Locations: University of Kansas Cancer Center, Westwood, Kansas
Conditions: Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
Register for Updates
ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies
NCT04412616
Recruiting
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2023
Locations: Kansas University Cancer Center, Fairway, Kansas
Conditions: Advanced EGFR Positive Solid Tumor
Register for Updates
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
NCT04680377
Recruiting
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2023
Locations: The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: NSCLC, Stage III, Locally Advanced Lung Carcinoma
Register for Updates